Ventripoint Diagnostics Ltd. Announces Strategic Initiatives to Strengthen Balance Sheet and Accelerate Commercialization of AI-Powered Echocardiography Technology

Toronto, Ontario — September 8, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. today announced several strategic initiatives aimed at strengthening its financial position and accelerating the commercialization of its artificial intelligence-enabled echocardiography technology. The company has secured US, Canadian, EU, and UK sales clearance for its proprietary VMS+™ platform.

These strategic moves include the successful closure of the initial tranche of a $350,000 non-brokered private placement, the engagement of More Capital Ltd. as a strategic growth advisor, and the appointment of Red Cloud Securities Inc. as a market maker. These actions are designed to enhance Ventripoint's financial flexibility, improve commercial execution, and boost market recognition as the company advances the widespread adoption of its VMS+™ platform.

Near-term objectives for Ventripoint involve expanding the market reach of VMS+, fostering strategic commercial partnerships, and increasing visibility among key stakeholders, including the cardiology, patient advocacy, and healthcare investment sectors.

First Tranche Financing

The Corporation has completed the first tranche of its non-brokered private placement, raising $180,000 through the issuance of Units at $0.10 per Unit. The company plans to conduct one or more additional tranches, pending regulatory approval, with the goal of raising up to $350,000 in gross proceeds. These funds will be allocated to the Corporation's commercialization program.

Each Unit comprises one common share and one common share purchase warrant. Each warrant allows the holder to acquire an additional common share at an exercise price of $0.14 for a period of 24 months post-closing. The warrants are subject to an accelerated expiry clause, where they may expire on 30 days' notice if the Corporation's common shares maintain a trading price of $0.30 or higher for 10 consecutive trading days.

The Corporation may offer cash finder's fees and issue finder's warrants, exercisable into common shares at $0.14 for 24 months, amounting to up to 8% of the offering's gross proceeds.

Proceeds from the offering will support sales and marketing efforts, the hiring of essential commercial personnel, and general working capital, all intended to expedite Ventripoint's commercialization timeline.

Related Party Transactions

Over the six months concluding June 30, 2026, directors and officers provided $115,000 in cash advances to the Corporation for operational needs, with repayment still outstanding. In May 2025, a director advanced $10,000 for operational purposes, which has since been repaid.

Further to a previous press release dated July 22, 2026, the issuance of shares for debentures constitutes a related party transaction under TSXV Policy 5.9 and Multilateral Instrument 61-101. Certain insiders will receive an aggregate of 48,383 common shares. The Corporation is utilizing exemptions from valuation and minority shareholder approval requirements under MI 61-101, as it is not listed on a specified market and the fair market value of insider participation does not exceed 25% of the Corporation's market capitalization, with the transaction's fair market value not exceeding $2,500,000.

Strategic Growth and Commercialization

Ventripoint has entered into a 12-month strategic growth and advisory agreement with More Capital, a Toronto-based firm, building upon their existing relationship announced on July 22, 2026. More Capital will focus on identifying and advancing commercial partnerships, supporting market expansion, evaluating strategic opportunities, and increasing awareness of Ventripoint's technology and commercialization initiatives, with a monthly compensation of $12,500.

Additionally, subject to TSX Venture Exchange (TSXV) approval, Ventripoint has engaged Red Cloud Securities Inc. to provide market stabilization and liquidity services. Red Cloud, a Toronto-based Investment Dealer and member of the Canadian Investment Regulatory Organization (CIRO), will trade Ventripoint shares on the TSXV to maintain a reasonable market and improve liquidity. The agreement, which can be terminated with 60 days' notice, provides Red Cloud with $5,000 per month and does not involve performance factors or compensation in shares or options.

“Ventripoint is entering an important phase as we shift from technology development to commercialization and scale,” said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. “This financing strengthens our balance sheet for the next stage of growth, while More Capital brings the strategic capabilities and relationships to help us accelerate partnerships, expand our market reach and build broader awareness of Ventripoint. Together, these initiatives position us to build a scalable commercial platform and drive the next stage of growth.”

Ventripoint has developed a proprietary AI-enabled approach to echocardiography that provides advanced quantitative cardiac analysis from ultrasound imaging. Its VMS+™ technology is designed for compatibility with ultrasound platforms from various manufacturers, enabling healthcare providers to access advanced cardiac analytics without needing to replace existing imaging equipment.

As commercialization progresses, Ventripoint aims to extend its technology platform to additional clinical applications and markets, while forging strategic relationships to scale the reach and impact of VMS+™ within cardiovascular care. VMS+™ systems are currently utilized in the U.S.A., Canada, the EU, the UK, and China.

About Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Ltd. is a leader in applying artificial intelligence to echocardiography. The Corporation's VMS+™ products leverage its proprietary Knowledge-Based Reconstruction (KBR) technology, the outcome of over a decade of development.

VMS+™ offers accurate volumetric cardiac measurements from standard echocardiography, comparable to MRI, while providing enhanced accessibility, speed, and affordability. This cost-effective, gold-standard alternative empowers cardiologists with greater confidence in patient management, without the need for cardiac MRI. Ventripoint's product development is driven by the goal of improving patient care.

VMS+™ is compatible with ultrasound systems from multiple manufacturers and holds regulatory market approvals in the United States, Europe, and Canada. Ventripoint is pursuing a global growth strategy focused on increasing adoption, building strategic partnerships, and expanding the applications of its technology across cardiovascular care.

Source: Ventripoint Diagnostics Ltd.